ANXA2 and prostate adenocarcinoma: Consistently with our findings, previous studies demonstrated a diagnostic value of ANXA2 in LIHC (Zhang et al., 2012b), PAAD (Zhang et al., 2022) and PRAD (Li et al., 2021).